Skip to main content

Home/ Health and Fitness Club/ Group items tagged Oral-health-recommendations-UK

Rss Feed Group items tagged

pharmacybiz

NHS Contract Overhaul Urged for Better Preventative Oral Care | Expert Report 2024 - 0 views

  •  
    The College of General Dentistry, in partnership with Haleon, has unveiled a new report outlining recommendations from oral health professionals on how to best improve the provision of preventative oral care. The report includes insight-driven recommendations to bridge the gap between the intentions and practical delivery of this care. Drawing on input from UK oral health professionals, the report highlighted the need for redesigned NHS contracts that would provide more time and financial support in giving preventative oral care advice. It also called for increased resources to offer consistent preventative oral healthcare education to combat misinformation and promote healthier habits. Other key recommendations from the report include: Working with the government to update the Delivering Better Oral Health Toolkit to make it simpler and more user-friendly. Launching a national communications campaign to tackle misinformation about oral care Encouraging businesses to include dental cover in their employee assistance programmes
pharmacybiz

Pfizer Vydura for Acute Migraines: NICE Draft Guidance - 0 views

  •  
    The National Institute for Health and Care Excellence (NICE) has released conclusive draft guidance, suggesting Pfizer's Vydura (rimegepant) as a choice for treating acute migraines in adults with or without aura. However, there is a caveat. This recommendation applies exclusively to individuals with a prior history of migraines, meeting one of the following criteria: At least 2 triptans were tried and they did not work well enough or Triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough. This drug was developed by the US-based Biohaven Pharmaceuticals, acquired by Pfizer in 2022, in an $11.6 billion deal. Nurtec ODT is the commercial name for the drug in the US, while the European Union approved the drug under the name Vydura in April 2022. NICE recommended rimegepant, an oral lyophilisate (dissolving wafer) and the first oral calcitonin gene-related peptide (CGRP) receptor antagonist for acute migraine treatment, to be taken at the onset of a migraine attack. Migraine affects one in seven people in the UK, often with a debilitating impact, Pfizer UK said in a statement. The condition entails symptoms such as head pain, vomiting, nausea, altered vision, fatigue, and heightened sensitivity to light, sound, and odours.
pharmacybiz

Groundbreaking Relief: NICE-Endorsed Atogepant for Migraines - 0 views

  •  
    Patients suffering from chronic and episodic migraine attacks are set to benefit from a groundbreaking recommendation by the National Institute for Health and Care Excellence (NICE) regarding a new medication. The atogepant, a first-of-its-kind preventive drug for migraine, offers hope for those grappling with this debilitating condition and can be taken orally. Published as part of the final guidance draft, NICE has greenlit the atogepant, also known as Aquipta and manufactured by AbbVie, as an option for preventing both chronic and episodic migraines in adults. Specifically, this recommendation is for individuals who have experienced at least four migraine days per month and have failed to find relief with at least three previous preventive treatments. With approximately 4.5 million people in the UK affected by various forms of migraine, this new recommendation marks a significant advancement in migraine management as the condition significantly impacts patients' day-to-day activities as well as places a heavy burden on the NHS and the wider economy.
1 - 3 of 3
Showing 20 items per page